The good news is that GSK is evidently satisfied that 100mg qD is the correct dose
I'm not sure if the 100 mg QD is the final dose as the other doses (10 mg to 90 mg QD) are still being tested in Phase 2 to complete the dose response curve. Apparently 100 mg QD showed similar response as 800 mg QD.
i think this is a net positive since it confirms the compound is moving forward (not that there was huge doubt in the first place since the drug was licensed fairly recently), but the JV does have a basketfull of drugs to mix and match so it is reassuring that the idix compound still seems likely to be an integral part of development plans moving forward a possible minor delay in the start of such a study is really trivial imo PS: the negative one can make of this is that lower doses than 100 did not have sufficient efficacy. i personally don't consider this clinically relevant since 100 is SUCH a low dose already and should easily lend itself to coformulation (in fact i was surprised they even bothered to examine lower doses - unless another agent they hoped to combine with idix899 required much higher dosing??)
Market Data 
Markets 
AI
